<DOC>
	<DOCNO>NCT01724177</DOCNO>
	<brief_summary>To evaluate efficacy lenalidomide patient Adult T-cell Leukemia-lymphoma ( ATL ) previously receive chemotherapy ATL .</brief_summary>
	<brief_title>A Phase 2 Study Lenalidomide Patients With Relapsed Recurrent Adult T-cell Leukemia-lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must understand voluntarily sign informed consent Aged 20 year old ( time signing informed consent ) Have document diagnosis either : acute , lymphoma , unfavorable chronictype adult Tcell leukemialymphoma Have receive ≥1 prior antiadult Tcell leukemialymphoma therapy , achieve stable disease well immediately prior therapy relapse progressed time obtain sign informed consent Subjects least 1 measurable lesion ( measurable lesion compute tomography scan , peripheral blood skin lesion ) confirm lesion assessment registration Have Eastern Cooperative Oncology Group performance status 0 2 registration Must able adhere study visit schedule protocol requirement Must agree comply Lenalidomide Pregnancy Prevention Risk Management Plan Have history central nervous system involvement present central nervous system symptom , diagnosed central nervous system lymphoma cerebrospinal fluid cytology examination , head compute tomography scan brain magnetic resonance imaging screen Are pregnant lactate Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . Examples medical condition , limited , follow : Uncontrolled diabetes mellitus define investigator subinvestigator Chronic congestive heart failure ( New York Heart Association Class III IV ) Unstable angina pectoris , angioplasty , stenting , myocardial infarction ( within 6 month start study drug ) Clinically significant cardiac arrhythmia symptomatic require treatment , asymptomatic sustain ventricular tachycardia ( subject control atrial fibrillation asymptomatic eligible study ) Major surgery within 28 day start study treatment Exhibit grade 4 neurological disorder Patients high risk thromboembolic event willing take venous thromboembolic prophylaxis . Develop active tuberculous disease , herpes simplex , systemic mycosis , active infection require systemic administration antibiotic , antiviral agent , antifungal drug Known human immunodeficiency virus positivity Have hepatitis B surface antigenpositive , hepatitis C virus antibody positive . In case hepatitis B core antibody and/or hepatitis B surface antibody positive even hepatitis B surface antigennegative , hepatitis B virus deoxyribonucleic acid test perform positive subject exclude Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study Have history allogenic stem cell transplantation Have receive autologous stem cell transplantation within 12 week ( 84 day ) start study treatment Have previously use lenalidomide Have history desquamating ( blister ) rash take thalidomide Have receive investigational drug ( unapproved drug Japan ) within 4 week ( 28 day ) start study medication Have receive antibody agent within 12 week ( 84 day ) start study medication Have receive chemotherapeutic agent immunomodulatory drug treatment adult Tcell leukemialymphoma within 4 week ( 28 day ) start study treatment Have receive radiotherapy within 4 week ( 28 day ) start study treatment Have history complication another malignant tumor adult Tcell leukemialymphoma follow malignant tumor , unless patient free disease 5 year longer Basal cell carcinoma skin Squamous cell carcinoma skin Cervical carcinoma situ Carcinoma situ breast An incidental histological finding prostate carcinoma ( TNM stage T1a T1b ) Earlystage gastric cancer treat endoscopic mucosal resection endoscopic submucosal dissection Have follow abnormal measurement screen perform within 1 week ( 7 day ) prior registration ; Neutrophil count : &lt; 1,200/µL Platelet count : &lt; 75,000/µL Serum aspartate aminotransferase/glutamyl oxaloacetic transaminase alanine aminotransferase/glutamyl pyruvic transaminase : &gt; 3 time upper limit normal Bilirubin level : &gt; 1.5 time upper limit normal Creatinine clearance : &lt; 60 mL/min Any condition confound ability interpret data study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>ATL</keyword>
	<keyword>ATLL</keyword>
</DOC>